Clinical Trials

Currently Recruiting


Recruiting
SNDX-5613-0700/AUGMENT-101
NCT04065399
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101).

Recruiting
SNDX-6352-0503
NCT03604692
A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD Activity of axatilimab (SNDX-6352) in Subjects With Active cGVHD Who Have Received at Least 2 Lines of Prior Therapy.

Recruiting
SNDX-6352-0502
NCT03238027
A Phase 1 Study to Investigate axatilimab (SNDX-6352) Alone or in Combination With Durvalumab in Patients With Solid Tumors.
NOT CURRENTLY RECRUITING

Entinostat in HR + Breast Cancer


Sponsored by NCI/ECOG-ACRIN Cancer Research Group
NCT02115282

A Randomized Phase 3 Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor
Positive Advanced Breast Cancer Whose Disease Has Progressed on A Nonsteroidal Aromatase Inhibitor.

Entinostat as Immunotherapy


Collaboration with Merck
NCT02437136

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients
With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma,
and Mismatch Repair-Proficient Colorectal Cancer.